-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $8

Benzinga·09/22/2025 09:30:42
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $21 to $8.